Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The Immunohistochemical Expression of the Oestrogen Receptor (ER), HER-2/NEU and Cytokeratin 8/18 and 5/6 in Invasive Breast Carcinoma.

Rattan B, Manjari M, Kahlon SK, Kalra N, Bhalla A, Paul S.

J Clin Diagn Res. 2012 Nov;6(9):1495-8. doi: 10.7860/JCDR/2012/4086.2542.

3.

Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.

Delgallo WD, Rodrigues JR, Bueno SP, Viero RM, Soares CT.

Cytopathology. 2010 Aug;21(4):259-66. doi: 10.1111/j.1365-2303.2009.00713.x. Epub 2009 Oct 15.

PMID:
19843143
4.

Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.

Verma S, Bal A, Joshi K, Arora S, Singh G.

APMIS. 2012 Dec;120(12):1008-19. doi: 10.1111/j.1600-0463.2012.02933.x. Epub 2012 Jul 26.

PMID:
23030684
5.

Prognostic significance of molecular classification of breast invasive ductal carcinoma.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.

PMID:
19082617
6.

Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S.

Ann Clin Lab Sci. 2006 Spring;36(2):137-43.

PMID:
16682508
7.

Expression of luminal and basal cytokeratins in human breast carcinoma.

Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO.

J Pathol. 2004 Jun;203(2):661-71.

PMID:
15141381
8.

Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up.

Moatamed NA, Wu A, Sarah K, Apple SK.

J Clin Pathol. 2015 Jun;68(6):484-7. doi: 10.1136/jclinpath-2014-202729. Epub 2015 Feb 20. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2.

PMID:
25710705
9.

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.

PMID:
17234468
10.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

PMID:
19414985
11.
12.

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.

Hum Pathol. 2006 Sep;37(9):1217-26. Epub 2006 Jul 18.

PMID:
16938528
13.

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.

Sung H, Garcia-Closas M, Chang-Claude J, Blows FM, Ali HR, Figueroa J, Nevanlinna H, Fagerholm R, Heikkilä P, Blomqvist C, Giles GG, Milne RL, Southey MC, McLean C, Mannermaa A, Kosma VM, Kataja V, Sironen R, Couch FJ, Olson JE, Hallberg E, Olswold C, Cox A, Cross SS, Kraft P, Tamimi RM, Eliassen AH, Schmidt MK, Bolla MK, Wang Q, Easton D, Howat WJ, Coulson P, Pharoah PD, Sherman ME, Yang XR.

Br J Cancer. 2016 Feb 2;114(3):298-304. doi: 10.1038/bjc.2015.437. Epub 2015 Dec 17.

14.
15.

Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre.

Chakrabarti S, Karmakar R, Barui G, Maity PK, Bandyopadhyay A, Roy A.

J Indian Med Assoc. 2012 Dec;110(12):876-9.

PMID:
23936949
16.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
17.

Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics.

Slobodova Z, Ehrmann J, Krejci V, Zapletalova J, Melichar B.

Neoplasma. 2011;58(3):189-97.

PMID:
21391734
18.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313
19.
20.

Invasive mammary carcinoma: assessment of HER-2/neu status by immunohistochemistry.

Pătrană N, Georgescu CV, Fota GL, Enache DE, Pirici E.

Rom J Morphol Embryol. 2012;53(3 Suppl):781-7.

Supplemental Content

Support Center